Board of Directors
Roger Pomerantz, M.D. President, Chief Executive Officer, and Chairman of the Board of Directors
Roger Pomerantz is the President, Chief Executive Officer, and Chairman of the Board of Directors of Seres. Prior to joining Seres, Dr. Pomerantz was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc., where he oversaw all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals, and academic alliances. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. Dr. Pomerantz earned his B.A. in biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his internal medicine internship and residency training, and his subspecialty clinical and research training in infectious diseases and virology at the Massachusetts General Hospital of Harvard Medical School. His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology (MIT), in the laboratory of Nobel Laureate Dr. David Baltimore. Dr. Pomerantz also served as the Chief Resident at the Massachusetts General Hospital. Following his medical-scientist training, he was an Endowed, Tenured Professor of Medicine and Molecular Pharmacology and Chairman of the Infectious Diseases Department of Thomas Jefferson University in Philadelphia. Dr. Pomerantz is an internationally recognized expert in HIV molecular pathogenesis and latency. He has developed ten approved infectious disease drugs in important diseases including HIV, HCV, tuberculosis, and Clostridium difficile infection.
Noubar Afeyan, Ph.D. Co-Founder Seres Therapeutics; Managing Partner and CEO, Flagship Pioneering
Noubar Afeyan is Managing Partner and CEO of Flagship Pioneering. He is a recognized technologist and entrepreneur. He has more than 25 years of experience as an inventor, entrepreneur, CEO, and venture capitalist. Dr. Afeyan has co-founded and helped build numerous successful life sciences companies and technology startups. He was founder and CEO of PerSeptive Biosystems, a leader in the bio-instrumentation field. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Dr. Afeyan was also a founder, director, and investor in Chemgenetics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), and Adnexus Therapeutics (acquired by Bristol-Myers Squibb). Dr. Afeyan currently serves on a number of public and private company boards including Affinnova, BG Medicine, Pronutria, Joule Unlimited, and Moderna Therapeutics. He earned his Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (MIT) in 1987.
Dennis Ausiello, M.D. Jackson Professor of Clinical Medicine at Harvard Medical School; Chair of Medicine, Emeritus at Massachusetts General Hospital
Dennis A. Ausiello is the Jackson Distinguished Professor of Clinical Medicine and Director, Emeritus of the MD/PhD Program at Harvard Medical School. He is also Chair of Medicine, Emeritus, and Director of the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital. He received his undergraduate degree from Harvard College and his medical degree from the University of Pennsylvania. Dr. Ausiello has made substantial contributions to the study of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. He has published numerous articles, book chapters, and textbooks, and served as an editor of Cecil's Textbook of Medicine.
Grégory Behar CEO, Nestlé Health Science S.A.
Grégory Behar has served as a member of our board of directors since December 2014. Mr. Behar has served as Chief Executive Officer of Nestlé Health Science S.A., a health sciences company, since October 2014. From July 2011 to July 2014, Mr. Behar was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. (USA), a pharmaceutical company. From 2010 to July 2011, Mr. Behar was Corporate Vice President Region NECAR (North European Union, Canada and Australasia) for Boehringer-Ingelheim GmbH, a pharmaceutical company. Mr. Behar received his B.S. from the University of California, Los Angeles, a M.S. in Mechanical Engineering and Manufacturing from EPFL in Switzerland and an MBA from INSEAD in France. We believe that Mr. Behar is qualified to serve on our board of directors because of his extensive business experience in the health sciences and pharmaceutical industries.
Kurt Graves Chairman, President and CEO, Intarcia Therapeutics, Inc.
Mr. Graves has been Chairman, President and CEO of Intarcia since April 2012, having previously served solely as Chairman of the company since August 2010 and as Acting CEO since October 2011. He is a global industry leader with more than twenty years of U.S. and global general management experience at top-tier U.S. and European based pharmaceutical and biotech companies. He has successfully built and managed several of the largest multi-billion dollar franchises in the industry and developed and launched more than 10 blockbuster brands in a broad range of general medicine, specialty and orphan disease areas. In addition to driving dynamic top and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early stage companies; at Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals. Prior to his tenure at Vertex, he spent nearly ten years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Prior to Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. In addition to Intarcia, Mr. Graves serves as Chairman of the Board of Radius therapeutics (RDUS), and as a Director at Achillion Pharmaceuticals (ACHN), Seres Therapeutics (MCRB). Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.
Lorence Kim, M.D. Chief Financial Officer, Moderna
Lorence Kim is the CFO of Moderna Therapeutics, a pioneer in messenger RNA therapeutics. Prior to joining Moderna, he was a managing director and co-head of the U.S. biotechnology investment banking effort at Goldman Sachs. He joined Goldman Sachs in 1999 as a summer associate and was named managing director in 2008. As a member of the Healthcare Investment Banking Group for nearly 14 years, Dr. Kim’s responsibilities included corporate finance and mergers and acquisitions for the pharmaceutical and biotechnology industries. Prior to joining Goldman Sachs, Dr. Kim worked in various medical research and consulting positions concurrent with his graduate studies. Dr. Kim earned his B.A. in biochemical sciences in 1995. He earned his M.B.A. in health care management as a Palmer Scholar from the Wharton School of the University of Pennsylvania in 2000, and his M.D. from the University of Pennsylvania’s School of Medicine in 2000.
Richard Kender Former Senior Vice President of Business Development and Corporate Licensing, Merck
Richard Kender is a retired executive with 35 years of experience in the pharmaceutical industry, most recently as Senior Vice President of Business Development and Corporate Licensing at Merck. Mr. Kender joined Merck in 1978 and spent his entire professional career, until his retirement in 2013, at the company in various corporate roles. At Merck, Mr. Kender was involved in more than 100 transactions of various size and type. He serves on the Board of Directors of INC Research Holdings, Inc., and has served on the Board of Directors of FoxHollow Technologies Inc. and EV3 Inc. Mr. Kender has also served on the Board of Trustees of BioNJ. Mr. Kender earned his B.S. in accounting from Villanova University and his M.B.A. from Fairleigh Dickinson University.
Willard Dere, M.D. Professor of Internal Medicine; B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical and Translational Scien
Dr. Dere serves as the Professor of Internal Medicine; B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center. Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. He joined Amgen in 2003 where he held multiple roles including head of global development, and both corporate and international chief medical officer. He led development of programs in various therapeutic areas, and retired from Amgen in October 2014. He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational and late-stage clinical research. Dr. Dere currently serves on the Board of Directors of BioMarin Pharmaceutical, Ocera Therapeutics, and Radius Health. He earned his undergraduate and medical degrees at the University of California, Davis, completed his internal medicine residency training at the University of Utah, and his postdoctoral training in endocrinology and metabolism at the University of California, San Francisco.
Meryl Zausner Former Executive Vice President and Chief Financial Officer, Novartis Pharmaceuticals
Meryl Zausner previously served as chief financial and administrative officer of Novartis Pharmaceuticals Corporation and a member of the U.S. Pharmaceutical Executive Committee and Global Finance Leadership Team. At Novartis, she was instrumental in the launch of the Oncology Business Unit, as well as the company’s shared services organization. Ms. Zausner was a member of the Novartis Global Oncology Leadership Team and played a key role in developing and commercializing leading therapies including Gleevec® (imatinib). Ms. Zausner is also currently a board member and chair of the audit committee for Neon Therapeutics, Inc. and the Multiple Myeloma Research Foundation. Ms. Zausner received a B.S. in accounting and economics from the University at Albany, SUNY.